5
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Induction of Tumour Hypoxia by FAA and TNF: Interaction with Bioreductive Drugs

, &
Pages 373-377 | Published online: 03 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Pauline J. Wood, Michael R. Horsman, Azza A. Khalil, Fritz Steinberg, Christian Streffer, Jens Overgaard, Ian J. Stratford & Gerald E. Adams. (1996) A Comparison of the Physiological Effects of RSU1069 and RB6145 in the SCCVII Murine Tumour. Acta Oncologica 35:8, pages 989-994.
Read now
I.J. Stratford, G.E. Adams, J.C.M. Bremner, S. Cole, H.S. Edwards, N. Robertson & P.J. Wood. (1994) Manipulation and Exploitation of the Tumour Environment for Therapeutic Benefit. International Journal of Radiation Biology 65:1, pages 85-94.
Read now
J.C.M. Bremner, C.J.R. Counsell, H.S. Edwards, I.J. Stratford, G.E. Adams, A.B.W. Nethersell & P. Bedford. (1991) Monitoring Metabolic Responses after Induction of Hypoxia in the KHT Tumour Using 31P NMR Spectroscopy. International Journal of Radiation Biology 60:1-2, pages 363-367.
Read now

Articles from other publishers (11)

Michael R. Horsman & Dietmar W. Siemann. (2006) Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies. Cancer Research 66:24, pages 11520-11539.
Crossref
Roger M Phillips. (1999) Inhibition of DT-diaphorase (NAD(P)H:Quinone oxidoreductase, ec 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Biochemical Pharmacology 58:2, pages 303-310.
Crossref
William R. Wilson & Frederik B. Pruijn. (2007) Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: HYPOXIA‐ACTIVATED PRODRUGS AS ANTITUMOUR AGENTS: STRATEGIES FOR MAXIMIZING TUMOUR CELL KILLING. Clinical and Experimental Pharmacology and Physiology 22:11, pages 881-885.
Crossref
Charles S. Parkins, Sally A. Hill, Sarah J. Lonergan, Michael R. Horsman, Jennifer A. Chadwick & David J. Chaplin. (1994) Ischaemia induced cell death in tumors: Importance of temperature and pH. International Journal of Radiation Oncology*Biology*Physics 29:3, pages 499-503.
Crossref
Stephen Cliffe, Maryann L. Taylor, Michael Rutland, Bruce C. Baguley, Richard P. Hill & William R. Wilson. (1994) Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. International Journal of Radiation Oncology*Biology*Physics 29:2, pages 373-377.
Crossref
Radhika Kalra, Jane C.M. Bremner, Pauline J. Wood, Janet Sansom, Christopher J.R. Counsell, Ian J. Stratford & Gerald E. Adams. (1994) 31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW 589C. International Journal of Radiation Oncology*Biology*Physics 29:2, pages 285-288.
Crossref
Gerald E. Adams & Ian J. Stratford. (1994) Bioreductive drugs for cancer therapy: The search for tumor specificity. International Journal of Radiation Oncology*Biology*Physics 29:2, pages 231-238.
Crossref
Paul Baas, Hugo Oppelaar, Mireile Stavenuiter, Nico Van Zandwijk & Fiona A Stewart. (1993) Interaction of the bioreductive drug sr 4233 and photodynamic therapy using photofrin in a mouse tumor model. International Journal of Radiation Oncology*Biology*Physics 27:3, pages 665-670.
Crossref
Jane C. M. Bremner. (1993) Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation. Cancer and Metastasis Reviews 12:2, pages 177-193.
Crossref
William A. Denny & William R. Wilson. (1993) Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer and Metastasis Reviews 12:2, pages 135-151.
Crossref
Christopher M. Riley, Bhasker V. Shetty, Nik C. Chetwyn, Virginia T. Kasper, Carl G. Kindberg & C.Michael Dicken. (1993) A stability-indicating assay and the preformulation characteristics of the radiosensitizer, 1,2,4-benzotriazin-3-amine 1,4-dioxide. Journal of Pharmaceutical and Biomedical Analysis 11:2, pages 131-138.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.